Literature DB >> 3296598

Glucokinase in pancreatic B-cells and its inhibition by alloxan.

S Lenzen, M Tiedge, U Panten.   

Abstract

Characterization of glucokinase in pancreatic B-cells from ob/ob mice and from rat liver revealed identical characteristics. A narrow substrate specificity; high Km values for the two substrates, D-glucose and D-mannose, in the range of 10 and 20 mmol/l, respectively; higher Vmax values for D-glucose than for D-mannose; inhibition of glucokinase activities by D-mannoheptulose and by a specific glucokinase antibody. These characteristics distinguish glucokinase in soluble cytoplasmic fractions of pancreatic B-cells and liver from low Km hexokinases. Alloxan is a pancreatic B-cell cytotoxic agent, which has been widely used as a tool for the elucidation of the mechanisms of insulin secretion, because its inhibitory action on insulin secretion has been presumed to be intimately related to the mechanism of glucose-induced insulin secretion. Alloxan inhibited glucokinase but not hexokinase activity in cytoplasmic fractions of pancreatic B-cells and liver. The half maximal inhibitory concentration of alloxan was 5 mumol/l. Glucokinase activity was protected from alloxan toxicity only by D-glucose and D-mannose; the alpha anomer of D-glucose provided significantly greater protection than the beta anomer. The non-metabolizable sugar 3-O-methyl-D-glucose did not provide protection of glucokinase activity against inhibition by alloxan. Thus, inhibition of pancreatic B-cell glucokinase may contribute to the inhibition of glucose-induced insulin secretion by alloxan. These results support the contention that glucokinase regulates the metabolic flux rate through the glycolytic chain in the pancreatic B-cell and thereby generates the signal for glucose-induced insulin secretion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3296598     DOI: 10.1530/acta.0.1150021

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  9 in total

1.  Chronic Exposure to Excess Nutrients Left-shifts the Concentration Dependence of Glucose-stimulated Insulin Secretion in Pancreatic β-Cells.

Authors:  Karel A Erion; Charles A Berdan; Nathan E Burritt; Barbara E Corkey; Jude T Deeney
Journal:  J Biol Chem       Date:  2015-05-01       Impact factor: 5.157

Review 2.  Minireview: The value of looking backward: the essential role of the hindbrain in counterregulatory responses to glucose deficit.

Authors:  Sue Ritter; Ai-Jun Li; Qing Wang; Thu T Dinh
Journal:  Endocrinology       Date:  2011-08-30       Impact factor: 4.736

Review 3.  Alloxan: history and mechanism of action.

Authors:  S Lenzen; U Panten
Journal:  Diabetologia       Date:  1988-06       Impact factor: 10.122

Review 4.  A fresh view of glycolysis and glucokinase regulation: history and current status.

Authors:  Sigurd Lenzen
Journal:  J Biol Chem       Date:  2014-03-17       Impact factor: 5.157

5.  Inhibition of aconitase by alloxan and the differential modes of protection of glucose, 3-O-methylglucose, and mannoheptulose.

Authors:  S Lenzen; M Mirzaie-Petri
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-11       Impact factor: 3.000

6.  Insulin secretion, insulin content and glucose phosphorylation in RINm5F insulinoma cells after transfection with human GLUT2 glucose-transporter cDNA.

Authors:  M Tiedge; M Höhne; S Lenzen
Journal:  Biochem J       Date:  1993-11-15       Impact factor: 3.857

7.  Relationship among brain and blood glucose levels and spontaneous and glucoprivic feeding.

Authors:  Ambrose A Dunn-Meynell; Nicole M Sanders; Douglas Compton; Thomas C Becker; Jun-ichi Eiki; Bei B Zhang; Barry E Levin
Journal:  J Neurosci       Date:  2009-05-27       Impact factor: 6.167

8.  Structural requirements of alloxan and ninhydrin for glucokinase inhibition and of glucose for protection against inhibition.

Authors:  S Lenzen; F H Brand; U Panten
Journal:  Br J Pharmacol       Date:  1988-11       Impact factor: 8.739

Review 9.  The mechanisms of alloxan- and streptozotocin-induced diabetes.

Authors:  S Lenzen
Journal:  Diabetologia       Date:  2007-12-18       Impact factor: 10.122

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.